Additional Listing on Exercise of Share Options

23 January 2014

Source BioScience plc("Source BioScience" or "the Company")

Additional Listing on Exercise of Share Options

Source BioScience plc (LSE: SBS) announces that it has issued 175,000 new ordinary shares of2 pence each in the Company ("Ordinary Shares"), following the election by certain option holders to exercise options under the Company's 2001 Approved Share Option scheme.

An application has been made for the Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. Admission of the Ordinary Shares will be made as soon as practical.

Following the issue and allotment, the Company's issued share capital will comprise 313,448,965 Ordinary Shares of 2 pence each. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Source BioScience plc under the FCA's Disclosure and Transparency Rules. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Enquiries

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0) 115 973 9010

Email: [email protected]

www.sourcebioscience.com

For investor and media enquiries:

N+1 Singer (Financial Advisor and Broker)

Aubrey Powell/ Joseph Stroud

Tel: +44 (0)20 7496 3000

www.n1singer.com

College Hill (PR Agency)

Melanie Toyne-Sewell/ Donia Al Saffar

Tel: +44 (0)20 7457 2020

Email: [email protected]

About Source BioScience:

Source BioScience plc (LSE: SBS) is an international laboratory services and products business serving the healthcare and life science research markets. The Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases in addition to complementary products for serology, diagnostics and sample storage. The LifeSciences division provides gene-based laboratory research support from conceptualisation to implementation, calling upon a wide range of innovative technology platforms and an online catalogue of biomolecular tools including cDNA clones and antibodies. The PharmaBiotech division provides support for drug discovery, from biomarker discovery and clinical trial services through to stability storage and sample archiving under environmentally controlled conditions. A superior quality management system, including GLP, GCP and CPA accreditations, make the services very attractive for applications in regulatory studies or in a clinical and diagnostic setting. Source BioScience has its headquarters in Nottingham, UK. For more information, see www.sourcebioscience.com.